

**Prescriber Information**

Prescriber Name:				MD	DO	NP	PA	NPI:
Office Contact:			Practice Name / Collaborating MD:					
Address:			City:			State:		Zip:
Phone:		Fax:						

**Patient Information • PLEASE SEND COPY OF INSURANCE CARD**

Patients Name:		Last 4 Digits of SS#:		DOB: / /	Sex: M F	Weight:	Height:	Diabetic? Y N
Address:			City:			State:		Zip:
Home Phone:		Work/Cell:		HIPAA Contact:			Emergency #:	
Interpreter Needed? Y N	Allergies: Y N <b>If Yes, list allergies:</b>							

**Insurance Information**

Primary Insurance:	Policy ID:	Group #:	BIN:	PCN:
Policyholder Name:		Policyholder DOB: / /		

**Clinical Information • PLEASE SEND COPY OF MEDICAL AND PRESCRIPTION INSURANCE CARDS, PROGRESS NOTES AND LAB REPORTS, SUPPORTING DIAGNOSIS, CO-MORBIDITIES AND LAB VALUES**

ICD-10/Diagnosis Code:	Pulmonary Eosinophilia (J82)		Moderate Persistent Asthma, uncomplicated (J45.40)		Severe Persistent Asthma, uncomplicated (J45.50)		Idiopathic Urticaria (L50.1)		
Atopic Dermatitis (L20.9)		Nasal Polyp (J33._____)		Eosinophilic esophagitis (K20)		Other:		FEV1: %	
Pre-treatment serum IgE: < 30 IU/mL   ≥30-100 IU/mL   > 100-200 IU/mL   > 200-300 IU/mL   > 300-400 IU/mL   > 400-500 IU/mL   > 500-600 IU/mL   > 600-700 IU/mL									
Patient medical history includes: Positive RAST   Positive skin test to perennial aeroallergen   Asthma with eosinophilic phenotype   Other:									
Current maintenance treatment (include dose and frequency):								Patient is a smoker or is exposed to smoke in the home: Y N	
Current exacerbation treatment (include dose and frequency):									
Prior Treatment? Y N (Provide Information Below)	BSA Affected (%):		Affected Areas: Palms   Soles   Head   Neck   Genitalia   Other:						
Prior Therapy:			Reason for Discontinuation of Therapy:					Approx. Start Date: / /	
								Approx. End Date: / /	
Comorbidities:				Concomitant Medications:					

**Prescription Information**

Medication	Quantity/Dose	Sig	Refills
<b>ADBRY™</b>	1 carton (4x150mg/mL)	<b>Starter Dose:</b> Inject 600mg (four 150mg injections) SQ at week 0. Begin maintenance dosing at week 2.	<b>No Refills</b>
	1 carton (2x150mg/mL)	<b>Maintenance Dose:</b> Inject 300mg (two 150mg injections) SQ every other week Inject 300mg (two 150mg injections) SQ every 4 weeks	
<b>CIBINQO™</b>	50mg tablet (30 day supply) 100mg tablet (30 day supply) 200mg tablet (30 day supply)	Take 1 tablet by mouth daily	
<b>DUPIXENT®</b> <i>*Asthma - Pediatrics (age 6-11)</i>	PFS Pen 1 carton (2x100mg/0.67ml) 1 carton (2x200mg/1.14ml) 1 carton (2x300mg/2ml)	<b>Weight 15-29kg:</b> Inject 100mg SQ every other week Inject 300mg SQ every 4 weeks <b>Weight ≥30kg</b> Inject 200mg SQ every other week	
<b>DUPIXENT®</b> <i>*Asthma - Adults &amp; Pediatrics aged 12 and older</i>	PFS Pen 1 carton (2x200mg/1.14ml) 1 carton (2x300mg/2ml)	<b>Starter Dose:</b> Inject 400mg SQ at week 0. Begin maintenance dose at week 2. Inject 600mg SQ at week 0. Begin maintenance dose at week 2.	<b>No Refills</b>
	1 carton (2x200mg/1.14ml) 1 carton (2x300mg/2ml)	<b>Maintenance Dose:</b> Inject 200mg SQ every 2 weeks Inject 300mg SQ every 2 weeks	
<b>DUPIXENT®</b> <i>*Atopic Dermatitis - Pediatrics (age 6 months to 5 years)</i> <i>*Dupixent pens only for use in children aged 2 or older</i>	PFS Pen 1 carton (2x200mg/1.14ml) 1 carton (2x300mg/2ml)	<b>Weight 5-14kg:</b> Inject 200mg SQ every 4 weeks <b>Weight 14-29kg:</b> Inject 300mg SQ every 4 weeks	
	<b>DUPIXENT®</b> <i>*Atopic Dermatitis - Pediatrics (age 6 &amp; older)</i>	PFS Pen 1 carton (2x200mg/1.14ml) 1 carton (2x300mg/2ml)	<b>Starter Dose:</b> <b>Weight 15-29kg:</b> Inject 600mg at week 0. Begin maintenance dose at week 4 <b>Weight 30-59kg:</b> Inject 400mg SQ at week 0. Begin maintenance dose at week 2. <b>Weight ≥60kg:</b> Inject 600mg SQ at week 0. Begin maintenance dose at week 2.
1 carton (2x200mg/1.14ml) 1 carton (2x300mg/2ml)		<b>Maintenance Dose:</b> <b>Weight 15-29kg:</b> Inject 300mg SQ every 4 weeks <b>Weight 30-59kg:</b> Inject 200mg SQ every 2 weeks <b>Weight ≥60kg:</b> Inject 300mg SQ every 2 weeks	
<b>DUPIXENT®</b> <i>*Atopic Dermatitis - Adults</i>	PFS Pen 1 carton (2x300mg/2ml)	<b>Starter Dose:</b> Inject 600mg SQ at week 0. Begin maintenance dose at week 2.	<b>No Refills</b>
	1 carton (2x300mg/2ml)	<b>Maintenance Dose:</b> Inject 300mg SQ every other week	
<b>DUPIXENT®</b> <i>*Chronic Rhinosinusitis with Nasal Polyps</i>	PFS Pen 1 carton (2x300mg/2mL)	Inject 300mg SQ every 2 weeks	
<b>DUPIXENT®</b> <i>*Eosinophilic Esophagitis (Adults and Pediatrics 1 year &amp; older)</i> <i>*Dupixent pens only for use in children aged 2 or older</i>	PFS Pen 1 carton (2x200mg/1.14ml) 1 carton (2x300mg/2ml)	<b>Weight 15-29kg:</b> Inject 200mg SQ every other week <b>Weight 30-39kg:</b> Inject 300mg SQ every other week <b>Weight ≥40kg:</b> Inject 300mg SQ once weekly	
	2 cartons (4x300mg/2ml)		

**Injection Training**

Patient received injection training	Prescriber's office to provide injection training	Meijer to coordinate injection training
-------------------------------------	---	---

By signing this form and utilizing our services, you are authorizing Meijer and its employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.

Prescriber Signature	Date	Prescriber Signature	Date
----------------------	------	----------------------	------

Substitution Permitted

Dispense as Written